Mealey's (September 24, 2018, 9:54 AM EDT) -- ALEXANDRIA, Va. — In a Sept. 20 final written decision, the Patent Trial and Appeal Board confirmed the patentability of 28 claims of a patented multidose, self-preserved ophthalmic composition for the treatment of glaucoma, marketed by Alcon Research Ltd. as “Travatan” (Argentum Pharmaceuticals LLC v. Alcon Research Ltd., No. IPR2017-01053, PTAB)....